Skip to main content
PIRAMAL PHARMA LIMITED logo

PIRAMAL PHARMA LIMITED — Investor Relations & Filings

Ticker · PPLPHARMA ISIN · INE0DK501011 LEI · 3358006D6AL7PZ4U9T51 BSE.NS Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2023-03-25 Audit Report / Informat…
Country IN India
Listing BSE.NS PPLPHARMA

About PIRAMAL PHARMA LIMITED

https://www.piramalpharma.com/

Piramal Pharma Limited provides a broad range of products and services across the drug lifecycle through three main business segments: Piramal Pharma Solutions, Piramal Critical Care, and Consumer Healthcare. Piramal Pharma Solutions operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering end-to-end services from drug discovery and development to commercial manufacturing of APIs and formulations. Piramal Critical Care focuses on complex hospital generics, holding a significant global market share in inhalation anesthetics, including Sevoflurane and Isoflurane, as well as injectable anesthesia and pain management therapies. The Consumer Healthcare division manages a diverse portfolio of over-the-counter brands such as Saridon, Lacto Calamine, and Tetmosol. The company leverages an extensive global manufacturing network to deliver specialized healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Audit Report / Information Classification · 95% confidence The document is a detailed communication from Piramal Pharma Limited to stock exchanges regarding the approval and issuance of restated consolidated financial information for fiscal years ending March 31, 2022 and March 31, 2021, and unaudited interim condensed consolidated financial information for nine months ended December 31, 2022 and 2021. It includes an Independent Auditor's Examination Report on the restated consolidated financial information, referencing compliance with Indian accounting standards and regulatory requirements related to a proposed rights issue. The document contains extensive financial statements and auditor's detailed examination and opinion, not merely an announcement or certification. The presence of comprehensive financial data, auditor's report, and restated financial statements indicates this is an Audit Report / Information filing rather than an Annual Report or Interim Report, as it focuses on audit examination of restated financials for a specific purpose (rights issue) rather than a full annual or quarterly report. Therefore, the appropriate classification is Audit Report / Information (AR). The document length (15,000 characters) and content confirm it is not a brief announcement or certification, so it is not RPA or RNS. 9M 2022
2023-03-25 English
Updates
Audit Report / Information Classification · 95% confidence The document is a detailed communication from Piramal Pharma Limited to stock exchanges regarding the approval and issuance of restated consolidated financial information for fiscal years ending March 31, 2022 and 2021, and unaudited interim condensed consolidated financial information for nine months ended December 31, 2022 and 2021. It includes an Independent Auditor's Examination Report on the restated consolidated financial information, referencing compliance with Indian accounting standards and regulatory requirements related to a proposed rights issue. The document contains extensive financial statements and auditor's detailed opinion, not merely an announcement or summary. The presence of the auditor's report and detailed financial data indicates this is an Audit Report / Information filing rather than an Annual Report or Interim Report, as it focuses on restated financials for a specific regulatory purpose (rights issue) and includes auditor examination rather than full annual reporting. It is not a brief announcement or certification, so it is not Regulatory Filings or Report Publication Announcement. Therefore, the document best fits the Audit Report / Information (AR) category. 9M 2022
2023-03-25 English
Updates
Major Shareholding Notification Classification · 95% confidence The document is a formal disclosure under SEBI Listing Regulations about the re-classification of certain entities from the 'Promoter Group' category to the 'Public' category for Piramal Pharma Limited. It includes approval letters from stock exchanges (BSE and NSE) confirming this reclassification. The content focuses on shareholding category changes and regulatory compliance disclosures rather than financial results, management changes, or other report types. The document length is 4285 characters, which is relatively short and primarily an announcement of a regulatory event. This fits the category of a Major Shareholding Notification (MRQ), as it involves changes in significant share ownership classification and related approvals. Therefore, the appropriate classification is MRQ with high confidence.
2023-03-23 English
Updates
Major Shareholding Notification Classification · 95% confidence The document is a disclosure under SEBI Listing Regulations regarding the re-classification of certain entities from 'Promoter Group' to 'Public' category. It is an announcement about changes in shareholding classification rather than a full report or financial statement. The content focuses on regulatory compliance and shareholding status updates, which aligns with notifications about major shareholding changes or classifications. Given the nature of the disclosure and the mention of promoter group re-classification, the most appropriate filing category is Major Shareholding Notification (MRQ). The document length is short and does not contain financial data or detailed reports, so it is not an Annual Report or Interim Report. Therefore, the classification is MRQ with high confidence.
2023-03-23 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed declaration of voting results from a postal ballot conducted by Piramal Pharma Limited. It references Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosure of voting results. The document includes vote counts, percentages, and the Scrutinizer's Report confirming the voting process and results. It does not contain financial statements, management discussion, or other report content but focuses solely on the official announcement of shareholder voting outcomes. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail confirm it is not a mere announcement of a report but the actual voting results declaration.
2023-03-22 English
Credit Rating
Capital/Financing Update Classification · 95% confidence The document is a notification under SEBI Listing Regulations about a credit rating revision by CARE Ratings Limited for various financial instruments of the company. It includes specific rating actions and instrument details but does not contain financial statements, management discussion, or detailed financial results. The document is short (1710 characters) and serves as an update on credit ratings, which relates to financing and capital structure information. Therefore, it fits best under Capital/Financing Update (CAP).
2023-03-06 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.